Ex-FDA women’s health official questions Plan B decision

Share this article:
The former top women's health official at the FDA, Susan Wood, said she believes the agency's refusal to approve OTC sales of Barr's Plan B was on orders from above, the Associated Press reported.
 "I don't think the FDA was acting independently," said Wood, who resigned last August after the FDA issued its decision on Plan B. Wood spoke to reporters after addressing the Center for American Progress, a Washington think tank.
Wood said she did not take part in the agency's decision on plan B and does not know for certain who made the call.
The final authority rested with then-FDA commissioner Lester Crawford, who resigned last month. The FDA reports to the Health and Human Services Department, which in turn reports to the White House.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...